LAT2

Across TCGA pan-cancer cohorts, LAT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LAT2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LAT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LAT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where LAT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.221	0.409	.001	20	view →
CCRCC	OS	Median	II,III,IV	0.617	0.953	.010	9	view →
LSCC	DFS	Median	II,III,IV	0.526	0.803	.030	6	view →
UCEC	DFS	Median	All	0.667	0.949	.026	4	view →
LUAD	DFS	Median	II,III,IV	0.770	0.338	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LAT2–PDAC (DFS)

Open the PDAC breakdown →